Recent reports suggest that Torrent Pharma, a prominent player in the pharmaceutical sector, is considering the acquisition of Cipla, another major pharmaceutical giant.
This has grabbed the attention of brokerages, who to get ahead of the curve, have written on Torrent Pharma, Cipla and the possible deal.
Another notable aspect that Nomura sees is costs and synergies in R&D and generics front-end, which could exceed around Rs 1,000 crore.
![](https://i1.wp.com/images.cnbctv18.com/wp-content/uploads/2023/09/iifl-pharma.jpg?ssl=1)
Torrent's scale in the US market could increase 6x โ it will get access to Ciplaโs rich pipeline of inhalation products as well as complex injectables. IIFL have a โbuyโ call on Torrent with a target price of Rs 2,400, on Cipla with a target price of Rs 1,150 and 'reduce' on Dr Reddys with a target price of Rs 3,900.